Tranexamic Acid: Nursing Drug Guide, Thromboembolism Risk & Hold Rules
Tranexamic acid stops fibrin breakdown—but that same antifibrinolytic action can trigger venous or arterial thromboembolism when clot screening is skipped, combined hormonal contraceptives overlap oral therapy, or IV product is given by the wrong route.
Tranexamic acid is an antifibrinolytic that may increase venous and arterial thrombosis or thromboembolism. IV Cyklokapron is contraindicated in active intravascular clotting and subarachnoid hemorrhage (risk of cerebral edema and infarction). Oral tablets for heavy menstrual bleeding are contraindicated with combined hormonal contraceptives and in active or high-risk thromboembolic disease. Avoid pro-thrombotic co-therapy (Factor IX complex concentrates, anti-inhibitor coagulant concentrates, hormonal contraceptives, all-trans retinoic acid) unless explicitly cleared by the prescriber. Cyklokapron is for intravenous use only—inadvertent neuraxial administration has caused seizures and arrhythmias. Hold immediately for new visual symptoms, suspected clot, or hypersensitivity; document screening and route verification before every dose.
📋 Contents
⚡ Quick facts
💡 Key takeaway
Before every tranexamic acid dose, confirm there is no active clot, no subarachnoid hemorrhage (IV), no combined hormonal contraceptive with oral tablets, and no pro-thrombotic co-therapy—then verify the correct route (IV product is never neuraxial) and renal-adjusted dose. Antifibrinolytic benefit disappears if thromboembolism develops on your shift.
Most common brand names
Tranexamic acid appears as generic tablets and injectable solutions, plus brand names that differ by country and indication. Always match the ordered formulation to the approved route and indication on the label.
Common names include Cyklokapron (IV injection, Pfizer) and Lysteda (oral tablets for cyclic heavy menstrual bleeding in the U.S.). Many hospitals stock generic tranexamic acid injection (100 mg/mL) and 650 mg oral tablets. Do not confuse tranexamic acid with aminocaproic acid (another antifibrinolytic) or with unrelated look-alike injectables stored nearby.
Why we give it — Indications
FDA-approved U.S. labeling in this guide covers hemophilia-related dental hemorrhage (IV) and cyclic heavy menstrual bleeding (oral). Other antifibrinolytic uses (trauma, postpartum hemorrhage, surgical bleeding) may appear in international guidelines or institutional protocols—verify indication, product, and dose against current prescribing information and local policy.
| Use | Detail |
|---|---|
| Hemophilia — tooth extraction (IV) | Cyklokapron is indicated in patients with hemophilia for short-term use (2 to 8 days) to reduce or prevent hemorrhage and reduce replacement therapy during and after tooth extraction. Administer with factor replacement per hematology protocol. |
| Cyclic heavy menstrual bleeding (oral) | Tranexamic acid tablets are indicated for treatment of cyclic heavy menstrual bleeding in females of reproductive potential. Prior to prescribing, endometrial pathology associated with heavy bleeding should be excluded per labeling. Nurses often see this for menorrhagia management in outpatient or ambulatory settings. |
On a small screen, swipe or scroll sideways to see the full table.
How it works
Tranexamic acid is a synthetic lysine analogue that binds plasminogen and blocks plasmin from degrading fibrin, preserving the fibrin matrix and reducing bleeding. Because it stabilizes clots, nursing care must balance hemorrhage control against thromboembolic risk—especially when patients already have clotting disorders, pro-thrombotic medications, or estrogen-containing contraception. Renal excretion means impaired kidney function prolongs exposure and requires dose reduction.
Dosing overview
Dosing depends on indication, route, weight, and renal function. Dosing must be verified against current prescribing information, prescriber order, renal/hepatic function, and local policy. Institutional protocols and product formulations may vary for off-label antifibrinolytic use.
Missed dose: Not specified in the reviewed prescribing information. For oral cyclic therapy, do not double doses; contact the prescriber or pharmacist for guidance if a dose is missed during the 5-day treatment window.
Onset, peak, duration, and half-life
| Parameter | Value | Nursing relevance |
|---|---|---|
| Onset | Not specified in the reviewed prescribing information for nursing summary | Antifibrinolytic effect is rapid enough for peri-procedural use; reassess bleeding and clot signs after each dose |
| Half-life (IV) | About 2 hours (terminal elimination phase after 1 g IV) | Renal impairment prolongs exposure—reduce dose per creatinine tables |
| Duration of antifibrinolytic effect | Antifibrinolytic concentration in tissues ~17 hours; serum up to 7–8 hours (IV labeling pharmacodynamics) | Thromboembolism risk may persist beyond a single dose—continue clot-symptom monitoring throughout therapy |
| Excretion | >95% unchanged in urine within 24 h after IV 10 mg/kg | Review serum creatinine before starting and during prolonged courses in at-risk patients |
On a small screen, swipe or scroll sideways to see the full table.
Before you give it — Safety check
For heavy menstrual bleeding, hold and clarify if the patient uses combined hormonal contraception, has active or prior thrombosis, retinal vessel occlusion, unexplained visual symptoms, or significant renal impairment. Oral tranexamic acid tablets are contraindicated with combined hormonal contraceptives per labeling; thromboembolism and retinal occlusion have been reported.
Pretreatment checks
- Confirm indication matches product (IV Cyklokapron vs oral tablets) and perform medication reconciliation for hormonal contraceptives, anticoagulants, and pro-thrombotic blood products
- Screen thrombosis history and active clot symptoms (deep vein thrombosis, pulmonary embolism, prior stroke or retinal occlusion)
- Review renal function (creatinine/eGFR), allergy status, subarachnoid hemorrhage diagnosis (IV contraindication), weight for mg/kg IV orders, and baseline vision complaints
Contraindications
- IV Cyklokapron: subarachnoid hemorrhage; active intravascular clotting; hypersensitivity to tranexamic acid or ingredients
- Oral tablets (HMB): concomitant combined hormonal contraceptives; active thromboembolic disease or history/intrinsic risk of thrombosis including retinal vein or artery occlusion; hypersensitivity
- All routes: do not administer IV Cyklokapron by intrathecal or epidural routes
Important interactions
| Drug / class | Effect | Nursing action |
|---|---|---|
| Combined hormonal contraceptives | Contraindicated with oral tablets; IV labeling warns pro-thrombotic co-use increases thromboembolism risk | Hold oral tranexamic acid if patient uses estrogen-containing contraception; confirm nonhormonal method or prescriber override before giving |
| Factor IX complex / anti-inhibitor coagulant concentrates | Increased thrombosis risk when combined with tranexamic acid | Avoid concomitant use per labeling; verify hematology orders and clarify with pharmacy if both appear on the MAR |
| All-trans retinoic acid (oral tretinoin) | Not recommended in acute promyelocytic leukemia during remission induction—may exacerbate procoagulant effect | Flag to oncology/pharmacy; do not administer without specialist clearance |
| Tissue plasminogen activators (tPA) | Concomitant use may decrease efficacy of both agents (oral tablet labeling) | Coordinate with stroke team or pharmacy when fibrinolytic and antifibrinolytic therapies overlap in protocol |
On a small screen, swipe or scroll sideways to see the full table.
Administration
Route: Oral tablets (swallow whole; may take with or without food) or IV infusion (Cyklokapron 100 mg/mL). Routes are not interchangeable.
- IV: Infuse no more than 1 mL/minute to avoid hypotension. Inspect solution for particulate matter and discoloration before use. Label syringes and bags IV only; use high-alert medication administration double-check when preparing injectable antifibrinolytics
- IV compatibility: May mix with common IV fluids; heparin may be added per Cyklokapron labeling. Do not mix with blood or penicillin-containing solutions
- Oral: Do not chew or break 650 mg tablets. Limit to maximum 5 days during each menstrual cycle per HMB labeling
Cyklokapron is for intravenous use only. Serious adverse reactions including seizures and cardiac arrhythmias have occurred when tranexamic acid was inadvertently administered intrathecally instead of intravenously. Confirm route, separate from spinal/epidural medications, and program IV infusion pump rates deliberately—never bolus IV tranexamic acid faster than labeling allows.
Expected therapeutic response
- Reduced bleeding during dental extraction in hemophilia patients when used with appropriate factor replacement
- Decrease in menstrual blood loss during the treated cycle for heavy menstrual bleeding (clinical trials used ≥80 mL baseline loss)
- Stable hemodynamics during IV infusion when rate ≤1 mL/min; ongoing monitoring for thrombosis despite improved bleeding control
Red flags — Stop and act
Stop tranexamic acid and escalate when thrombotic, neurologic, visual, or hypersensitivity events occur. Antifibrinolytic therapy can control bleeding while a clot forms elsewhere.
- Unilateral leg swelling, pain, warmth, or redness suggesting deep vein thrombosis
- Sudden chest pain, dyspnea, or tachycardia suggesting pulmonary embolism
- New focal neurologic deficits, severe headache, or seizures—especially after wrong-route injection
- Visual changes, blurred vision, or color vision disturbance (possible retinal artery/vein occlusion per labeling)—discontinue immediately and arrange ophthalmic evaluation
- Facial swelling, urticaria, bronchospasm, or hypotension after dose suggesting anaphylaxis—stop and treat per protocol; do not rechallenge
Adverse effects
| Adverse effect | Frequency / severity | Nursing response |
|---|---|---|
| Nausea, vomiting, diarrhea | Common (IV postmarketing); may resolve with dose reduction | Supportive care; slow IV rate; differentiate from thromboembolism symptoms |
| Hypotension | Reported when IV injection too rapid | Ensure infusion ≤1 mL/min; monitor blood pressure during IV doses |
| Dizziness, giddiness | Reported (IV); headache common in oral HMB trials (≥5%) | Fall precautions; advise patient not to drive until response known; evaluate for visual or neurologic causes |
| Thromboembolic events (DVT, PE, stroke, retinal occlusion) | Serious; reported with tranexamic acid | Hold drug, notify prescriber urgently, initiate thrombosis pathway per protocol |
| Seizures | Serious; linked to neuraxial error or high-dose surgical use | Stop infusion, protect airway, notify prescriber, document route and dose given |
| Hypersensitivity / anaphylaxis | Rare but serious | Discontinue permanently; emergency treatment per protocol |
On a small screen, swipe or scroll sideways to see the full table.
Overdose, toxicity, and antidote
Cyklokapron overdosage has been reported. Oral overdosage data are limited in the reviewed prescribing information.
Reported overdose symptoms
- Gastrointestinal: nausea, vomiting, diarrhea
- Hypotension: orthostatic symptoms (often with rapid IV administration)
- Thromboembolic: arterial, venous, or embolic events
- Neurologic: visual impairment, convulsions, headache, mental status changes, myoclonus
- Dermatologic: rash
Antidote
No specific antidote is listed in the reviewed prescribing information; management is supportive and guided by poison control or medical toxicology services per facility protocol and local emergency guidance. Treat hypotension, seizures, and thromboembolism per acute care pathways.
Contact local poison control or medical toxicology services for overdose or wrong-route administration guidance per facility protocol. Document amount, route, time, and clinical status.
Look-alike / sound-alike and error prevention
- Tranexamic acid vs aminocaproic acid — both antifibrinolytics with different dosing; verify drug name on MAR and vial
- Cyklokapron vs similarly named injectables — store separately; label “IV ONLY — NOT FOR SPINAL/EPIDURAL USE”
- Oral tranexamic acid vs IV formulation — never substitute route when only one formulation is ordered
- TXA abbreviation — use full drug name in high-risk discussions and patient teaching when feasible
- Combined hormonal contraceptive overlap — reconcile birth control patches, rings, and pills separately from “tranexamic acid” on the MAR
No specific look-alike/sound-alike pair is singled out in FDA labeling, but route confusion and antifibrinolytic class confusion remain high-impact errors.
Practical bedside notes
| Topic | Bedside guidance |
|---|---|
| Crush/split | Oral HMB tablets: swallow whole; do not chew or break apart per labeling |
| Food timing | Oral tablets may be given with or without food |
| IV rate | Maximum 1 mL/minute (100 mg/min at 100 mg/mL concentration) |
| Lab timing | Check creatinine before oral therapy if Cr >1.4 mg/dL threshold applies; trend during prolonged IV courses |
| Missed dose | Not specified in the reviewed prescribing information—contact prescriber or pharmacist |
| Commonly missed | Combined hormonal contraceptive on home med list; prior DVT not flagged on admission; IV syringe unlabeled near neuraxial kits |
| Ask pharmacy when | Renal dose unclear, contraceptive interaction, hematology co-therapy with factor concentrates, or suspected wrong-route administration |
On a small screen, swipe or scroll sideways to see the full table.
High-risk populations
| Population | Considerations |
|---|---|
| Thrombosis history or hypercoagulable states | Oral tablets contraindicated in active thromboembolic disease and history/intrinsic thrombosis risk including retinal occlusion. Use extreme caution and specialist oversight if antifibrinolytic therapy is considered |
| Combined hormonal contraceptive users | Contraindicated with oral tranexamic acid; IV labeling also warns against pro-thrombotic co-use. Advise effective nonhormonal contraception |
| Renal impairment / older adults | Drug is substantially renally excreted; elderly patients more often have reduced renal function—reduce dose per creatinine tables and monitor for toxicity |
| Subarachnoid hemorrhage | IV Cyklokapron contraindicated—labeling cites risk of cerebral edema and cerebral infarction |
| Pregnancy | Tranexamic acid crosses the placenta (cord levels ~30 mg/L after maternal 10 mg/kg IV per labeling). Human data have not clarified miscarriage or fetal risk; use only when maternal benefit outweighs potential fetal risk after prescriber risk–benefit evaluation |
| Lactation | Published literature reports tranexamic acid in human milk; effects on breastfed infant and milk production are not established in labeling. Weigh benefits of breastfeeding against clinical need for therapy and potential infant exposure |
On a small screen, swipe or scroll sideways to see the full table.
Monitoring and documentation
Monitor
- Signs of thromboembolism: leg pain/swelling, chest pain, dyspnea, neurologic changes, visual disturbances
- Vital signs during IV infusion—especially blood pressure if infusion faster than 1 mL/min
- Renal function (serum creatinine/eGFR) when dosing in impairment or prolonged therapy; bleeding response and complete blood count trends when clinically indicated
Document
- Indication, dose, route, weight-based calculation for IV mg/kg orders, infusion rate, and contraceptive/thrombosis screening completed
- Hold actions, prescriber/pharmacy notifications, and patient symptoms suggesting clot or visual toxicity
- Patient teaching on thrombosis symptoms, visual changes, dizziness/driving, and maximum days of oral therapy per cycle
Patient teaching
- Take oral tablets only during the heaviest days of menstruation, for a maximum of 5 days per cycle, and swallow tablets whole
- Do not use combined hormonal contraceptives (pill, patch, ring) while taking oral tranexamic acid unless your prescriber has switched you to a nonhormonal method
- Seek urgent care for leg swelling or pain, chest pain, sudden severe headache, trouble breathing, or any vision changes—stop the medication and call your clinician
- Report dizziness before driving or operating machinery; IV doses require bed rest or supervision during infusion if dizzy
- Tell all clinicians and pharmacists you are taking tranexamic acid before starting new medications, surgery, or hormone therapy
The Hold Rule
Do not give and contact the prescriber/pharmacist when:
- Active intravascular clotting or suspected new thromboembolism (DVT, PE, stroke symptoms)
- Subarachnoid hemorrhage diagnosis for IV Cyklokapron orders
- Combined hormonal contraceptive use with oral tranexamic acid, or unresolved pro-thrombotic drug interaction (Factor IX complex, anti-inhibitor concentrates, oral tretinoin in APL)
- Known tranexamic acid allergy or active hypersensitivity reaction
- New visual or ocular symptoms, seizure activity, or order for intrathecal/epidural administration of IV formulation
- Creatinine above thresholds requiring renal dose adjustment when the order does not reflect reduced dosing
Hold parameters may vary by institutional protocol. Follow prescriber orders, pharmacy guidance, and facility policy.
Clinical practice integration and workflow
Antifibrinolytic nursing is thrombosis prevention as much as bleeding control—screen before you draw up, verify route before you connect, and reassess clot symptoms after you infuse.
1. Check-before-you-give protocol
- Right patient, indication, and formulation (oral vs IV)
- Thrombosis and contraceptive history reconciled on admission and each cycle
- Renal function reviewed; mg/kg IV dose calculated from actual body weight
- IV line verified as peripheral/central venous—not neuraxial; syringe labeled IV ONLY
2. High-alert and safety badge
Not on standard high-alert lists — thromboembolism and wrong-route risk remain criticalMany institutions treat IV antifibrinolytics as high-risk infusions because of seizure risk with neuraxial error and hypotension with rapid injection. Follow local high-alert policy if applicable.
3. Clinical workflow: hold and question rules
- If the MAR shows oral tranexamic acid and an estrogen-containing contraceptive, hold and call pharmacy before the first dose—contraindicated combination
- If a postoperative patient develops unilateral calf pain on tranexamic acid, stop the drug and activate thrombosis assessment even if surgical bleeding improved
- If an IV bag is prepared near spinal anesthesia supplies, relocate preparation and re-verify route with a second nurse
4. Critical teach-back questions
- “What symptoms mean you should stop tranexamic acid and seek care right away?” (Leg swelling/pain, chest pain, breathing difficulty, sudden severe headache, vision changes.)
- “Can you use your usual birth control pill while taking this medication?” (No for combined hormonal contraceptives with oral tranexamic acid—use a nonhormonal method unless the prescriber changed therapy.)
5. Care coordination
Pharmacist: Renal dose adjustment, contraceptive interaction checks, IV compatibility questions, and overdose/wrong-route guidance with toxicology services
Hematology / prescriber: Coordinate with factor replacement in hemophilia, clarify thrombosis risk in patients with clot history, and manage hold/ restart decisions after visual or thrombotic events
🧠 Quick mental checklist
- Any active clot, clot symptoms, or subarachnoid hemorrhage on this patient?
- Is the patient on combined hormonal contraception while oral tranexamic acid is ordered?
- Renal function checked and dose adjusted for creatinine?
- IV route confirmed—not spinal/epidural—and infusion rate ≤1 mL/min?
- Have I taught the patient thrombosis and vision red flags before discharge?
Tranexamic Acid NCLEX practice questions
Rehearse NCLEX-style clinical judgment practice for tranexamic acid using a tabbed outpatient case (MAR, labs, history, nursing notes), then priority action, thrombosis-risk SATA, trend interpretation, matrix urgency sorting, IV route judgment, and documentation cloze—recognise cues → analyse clot risk → prioritise hold/escalation → act → evaluate outcomes. For heavy menstrual bleeding, hold and clarify if the patient uses combined hormonal contraception, has active or prior thrombosis, retinal vessel occlusion, unexplained visual symptoms, or significant renal impairment.
Select a tab to view MAR, labs, history, and nursing note details for this case.
- Tranexamic acid 650 mg tablets — 1300 mg PO TID × 5 days (0900, 1500, 2100)
- 0900 dose given; 1500 dose due now
- Ethinyl estradiol/norethindrone 1/20 mcg PO daily (combined oral contraceptive) — active on MAR
- Ibuprofen 400 mg PO PRN cramps — not given today
- Creatinine 1.6 mg/dL (baseline 1.5 mg/dL) — above 1.4 mg/dL oral adjustment threshold
- eGFR 48 mL/min/1.73 m²
- Hemoglobin 10.8 g/dL; platelets 265 ×10³/µL
- No coagulation panel drawn this visit
- 34-year-old with cyclic heavy menstrual bleeding; endometrial pathology excluded per gynecology
- History of left-leg DVT age 28 while on combined OCP — completed 6 months anticoagulation
- Non-smoker; BMI 31 kg/m²
- No known drug allergies
- 1400: Patient reports mild nausea after morning dose; vitals stable
- 1415: States she “cannot miss a pill” of her birth control and asks why tranexamic acid was added
- 1420: Nurse reviewing MAR, labs, and history tabs before 1500 dose
Answer key & rationale
Frequently asked questions
Can tranexamic acid be given with combined hormonal contraceptives?
No for oral tablets used for heavy menstrual bleeding — concomitant use with combined hormonal contraceptives is contraindicated because antifibrinolytic therapy plus estrogen-containing contraception further increases thromboembolism risk per tablet labeling. IV Cyklokapron labeling also warns against pro-thrombotic products including hormonal contraceptives. Advise nonhormonal contraception when tranexamic acid is required.
When should a nurse hold tranexamic acid?
Hold and contact the prescriber or pharmacist for active intravascular clotting, subarachnoid hemorrhage (IV contraindication), history or high intrinsic thrombosis risk when oral labeling applies, combined hormonal contraceptive use with oral tranexamic acid, known hypersensitivity, new visual or ocular symptoms, suspected thromboembolism, or any order for neuraxial/intrathecal administration.
What is the correct IV infusion rate for Cyklokapron?
Cyklokapron prescribing information states infuse no more than 1 mL/minute to avoid hypotension. The product is for intravenous use only — never administer intrathecally or epidurally; inadvertent neuraxial injection has caused seizures and arrhythmias.
Does tranexamic acid require renal dose adjustment?
Yes when renal function is impaired. IV Cyklokapron reduces frequency based on serum creatinine (for example, 10 mg/kg twice daily when creatinine is 1.36–2.83 mg/dL). Oral tablets for heavy menstrual bleeding reduce daily dose when creatinine is above 1.4 mg/dL. Verify current labeling and pharmacy guidance for the specific product and indication.
Is there a specific antidote for tranexamic acid overdose?
No specific antidote is listed in the reviewed prescribing information. Overdose may present with gastrointestinal symptoms, hypotension, thromboembolic events, visual changes, convulsions, or altered mental status. Management is supportive; contact local poison control or medical toxicology services per facility protocol and local emergency guidance.
References
-
U.S. National Library of Medicine. CYKLOKAPRON (tranexamic acid) injection — Full prescribing information. DailyMed. Revised April 2024; label updated January 2025.https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6e89a7d9-4da4-42aa-b7f8-c602c24eefe5
-
U.S. National Library of Medicine. Tranexamic acid tablets — Full prescribing information. DailyMed. Revised October 2023.https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=773eb919-7d48-4ba2-af58-aa169f0ea75f
-
Drugs and Lactation Database (LactMed). Tranexamic acid. Bethesda (MD): National Institute of Child Health and Human Development.https://www.ncbi.nlm.nih.gov/books/n/lactmed/LM828/
-
World Health Organization. WHO guideline for the use of tranexamic acid in post-partum haemorrhage. Geneva: World Health Organization; 2023.https://www.who.int/publications/i/item/WHO-guideline-for-the-use-of-tranexamic-acid-in-post-partum-haemorrhage
-
U.S. Food and Drug Administration. CYKLOKAPRON (tranexamic acid) injection — Prescribing information PDF. NDA 019281.https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/019281s047lbl.pdf
Review and transparency
This medication guide is written and reviewed using NurseOnShift editorial and clinical review standards.
Educational use only. This content does not replace clinical judgment, prescriber orders, pharmacist guidance, product labeling, or institutional protocols.